SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Jurgute R. R.)
 

Search: WFRF:(Jurgute R. R.) > (2021) > Direct and Indirect...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Li, X. (author)

Direct and Indirect Costs of Influenza-Like Illness Treated with and Without Oseltamivir in 15 European Countries: A Descriptive Analysis Alongside the Randomised Controlled ALIC(4)E Trial

  • Article/chapterEnglish2021

Publisher, publication year, extent ...

  • 2021-07-22
  • Springer Science and Business Media LLC,2021

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/306940
  • https://gup.ub.gu.se/publication/306940URI
  • https://doi.org/10.1007/s40261-021-01057-yDOI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background and Objective Influenza-like illness (ILI) leads to a substantial disease burden every winter in Europe; however, oseltamivir is not frequently prescribed to ILI patients in the primary-care setting. An open-label, multi-country, multi-season, randomised controlled trial investigated the effectiveness of oseltamivir for treating ILI in 15 European countries. We aimed to evaluate whether patients presenting with ILI in primary care and being managed with the addition of oseltamivir to usual care had lower average direct and indirect costs compared to patients with usual care alone. Methods Resource use data were extracted from participants' daily diaries. Itemised country-specific unit costs were collected through official tariffs, pharmacies or literature. Costs were converted to 2018 values. The null hypothesis was tested based on one-sided credible intervals (CrIs) obtained by bootstrapping. Base-case analysis estimated direct cost and productivity losses using itemised costed resource use and the human capital approach. Scenario analyses with self-reported spending rather than itemised costing were also performed. Results Patients receiving oseltamivir (N = 1306) reported fewer healthcare visits, medication uses, hospital attendances and paid-work hours lost than the other patients (N = 1298). Excluding the oseltamivir cost, the average direct costs were lower in patients treated with oseltamivir from all perspectives, but these differences were not statistically significant (perspective of patient: euro17 [0-95% Crl: 16-19] vs. euro24 [5-100% Crl: 18-29]; healthcare provider: euro37 [28-67] vs. euro44 [25-55]; healthcare payers: euro54 [45-85] vs. euro68 [45-81]; and society: euro423 [399-478] vs. euro451 [390-478]). Scenario and age-group analyses confirmed these findings, but with some between-country differences. Conclusion The average direct and indirect costs were consistently lower in patients treated with oseltamivir than in patients without from four perspectives (excluding the oseltamivir cost). However, these differences were not statistically significant.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Bilcke, J. (author)
  • van der Velden, A. W. (author)
  • Bongard, E. (author)
  • Bruyndonckx, R. (author)
  • Sundvall, Pär-DanielGothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för samhällsmedicin och folkhälsa,Institute of Medicine, School of Public Health and Community Medicine(Swepub:gu)xsupar (author)
  • Harbin, N. J. (author)
  • Coenen, S. (author)
  • Francis, N. (author)
  • Bruno, P. (author)
  • Garcia-Sangenis, A. (author)
  • Glinz, D. (author)
  • Kosiek, K. (author)
  • Miko-Pauer, R. (author)
  • Jurgute, R. R. (author)
  • Seifert, B. (author)
  • Tsakountakis, N. (author)
  • Aabenhus, R. (author)
  • Butler, C. C. (author)
  • Beutels, P. (author)
  • Göteborgs universitetInstitutionen för medicin, avdelningen för samhällsmedicin och folkhälsa (creator_code:org_t)

Related titles

  • In:Clinical Drug Investigation: Springer Science and Business Media LLC41:8, s. 685-6991173-25631179-1918

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view